Medherant Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $6.79M
Latest Deal Amount
  • Investors
  • 2

Medherant General Information

Description

Developer of a novel drug-in-adhesive transdermal delivery system designed to deliver higher doses of drugs through the skin. The company's drug delivery system comprises of a novel adhesive into which the drug to be delivered is mixed and has a greater loading capacity than other drug-in-adhesive patch technologies, enabling patients to take medicines in higher concentrations with faster release rates and without the complications associated with oral drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Primary Office
  • The Venture Centre
  • University of Warwick Science Park, Sir William Lyons Road
  • Coventry CV4 7EZ
  • England, United Kingdom
+44 024 0000 0000

Medherant Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medherant Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 12-May-2021 $6.79M 000.00 000.00 Completed Clinical Trials - General
4. Early Stage VC 18-Jan-2018 00.000 00.000 000.00 Completed Clinical Trials - General
3. Early Stage VC 20-Oct-2016 00.000 00.000 00.000 Completed Startup
2. Early Stage VC 24-Mar-2016 $570K $1.02M 00.000 Completed Startup
1. Seed Round 25-Mar-2015 $448K $448K 00.000 Completed Startup
To view Medherant’s complete valuation and funding history, request access »

Medherant Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Ordinary 000 0000.00 0000.00 00 0000.00 0.000
B Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
B Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
B Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
B Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
B Ordinary 7,444 $0.013895 $261.25 $261.25 1x $261.25 10.63%
Ordinary 84 $0.013895 $166.75 $166.75 1x $166.75 0.12%
To view Medherant’s complete cap table history, request access »

Medherant Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel drug-in-adhesive transdermal delivery system designed to deliver higher doses of drugs through the
Drug Delivery
Coventry, United Kingdom
16 As of 2021
000.00
00.00 0000-00-00
0000000000 0 000.00

00000000

niam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute i
0000 00000000
Miami, FL
00 As of 0000
000000000 -

000 0000

re magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000000 00000000
Andernach, Germany
0000 As of 0000
0.00 0000-00-00
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Medherant Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prosolus Corporate Backed or Acquired Miami, FL 00 000000000 -
000 0000000 000000 Formerly PE-Backed Andernach, Germany 0000 000000000000
000000000 Formerly Angel backed Orlando, FL 0 00.000 000000000 00.000
0000 0000000000000 Formerly Angel backed Oxnard, CA 00 0000 000000000 - 0000
000000 000000 Formerly VC-backed Fremont, CA 00 00000 00000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

Medherant Executive Team (7)

Name Title Board Seat Contact Info
William Burt Ph.D Chief Executive Officer & Board Member
Sally Waterman Ph.D Chief Operating Officer & Board Member
David Haddleton Co-Founder, Chief Scientific Officer & Board Member
Andrew Lee Ph.D Director of Commercial Development
Nigel Davis Ph.D Co-Founder & Chief Business Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Medherant Board Members (8)

Name Representing Role Since
Andrew McLean Self Board Member 000 0000
David Haddleton Medherant Co-Founder, Chief Scientific Officer & Board Member 000 0000
Kenneth Cunningham MD Self Chairman 000 0000
Mark Payton Ph.D Mercia Asset Management Board Member 000 0000
Sally Waterman Ph.D Medherant Chief Operating Officer & Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Medherant Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medherant Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovate UK Government Minority 000 0000 000000 0
Mercia Asset Management Venture Capital Minority 000 0000 000000 0
To view Medherant’s complete investors history, request access »